Share

Back to Search Results

Description
Details
Sub-Projects
Publications
Patents
Outcomes
Clinical Studies
News and More
History
Similar Projects

Adjuvant development in the context of seasonal and pandemic influenza

Project Number
272201800048C-P00001-9999-1

Contact PI/Project Leader
EVANS, JAY

Awardee Organization
UNIVERSITY OF MONTANA

Description

Abstract Text

This contract supports the development of an adjuvant through immunological characterization studies and compound optimization, up to and including IND-enabling studies. The main emphasis will be on testing and further development of the adjuvant for human licensure as a component of a licensed or investigational vaccine to protect against one or more non-HIV disease pathogens relevant to human disease.

Public Health Relevance Statement

Data not available.

NIH Spending Category

Bioengineering Clinical Research Emerging Infectious Diseases Immunization Infectious Diseases Influenza Nanotechnology Pneumonia & Influenza Vaccine Related

Project Terms

Adjuvant Development Disease Human Immunologics Influenza Influenza A Virus, H7N9 Subtype Influenza B Virus Investigation Licensure Ligands Support Contracts System TLR4 gene TLR7 gene Testing Vaccines human disease nanoparticle **pandemic** disease **pandemic** influenza pathogen seasonal influenza

Details

Contact PI/ Project Leader

Name
EVANS, JAY

Title

Contact
Email not available

Other PIs

Not Applicable

Program Official

Name

Contact
Email not available

Thank you for your feedback!

Organization

Name
UNIVERSITY OF MONTANA

City
MISSOULA

Country
UNITED STATES (US)

Department Type
Unavailable

Organization Type
Domestic Higher Education

State Code
MT

Congressional District
At-Large

Other Information

FOA

Study Section

Fiscal Year
2019

Award Notice Date

Administering Institutes or Centers
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

DUNS Number
010379790

CFDA Code

Project Start Date
30-September-2018

Project End Date
30-September-2023

Budget Start Date

Budget End Date

Project Funding Information for 2019

Total Funding
$3,308,745

Direct Costs
$0

Indirect Costs
$0

Year	Funding IC	
2019	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	$3,308,745

NIH Categorical Spending

Click here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	$3,308,745	Bioengineering; Clinical Research; Emerging Infectious Diseases; Influenza; Nanotechnology; Pneumonia & Influenza; Vaccine Related

Sub Projects

No Sub Projects information available for 272201800048C-P00001-9999-1

Publications

No Publications available for 272201800048C-P00001-9999-1

Thank you for your feedback!

Patents

No Patents information available for 272201800048C-P00001-9999-1

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 272201800048C-P00001-9999-1

Clinical Studies

No Clinical Studies information available for 272201800048C-P00001-9999-1

News and More

Related News Releases

No news release information available for 272201800048C-P00001-9999-1

History

No Historical information available for 272201800048C-P00001-9999-1

Similar Projects

No Similar Projects information available for 272201800048C-P00001-9999-1

Thank you for your feedback!